Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ1 | P48048 | 11/20 | 0.51 |
| ▸ | SRC | P12931 | 6/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.39 |
| ▸ | TNK1 | Q13470 | 1/20 | 0.39 |
| ▸ | RET | P07949 | 2/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30445347 | 0.81 | KCNJ1 (0.49) | KCNJ1 | |
| SCHEMBL20168538 | 0.81 | KCNJ1 (0.49) | KCNJ1 | |
| SCHEMBL13075902 | 0.80 | SRC (0.48) | KCNJ1SRCPARP1TNK2TNK1 | |
| SCHEMBL30444731 | 0.76 | KCNJ1 (0.51) | KCNJ1KCNH2 | |
| SCHEMBL20575376 | 0.76 | KCNJ1 (0.51) | KCNJ1KCNH2 | |
| SCHEMBL22606728 | 0.76 | KCNJ1 (0.57) | KCNJ1 | |
| SCHEMBL23560759 | 0.75 | CHRNB2 (0.47) | KCNJ1PARP1TNK2TNK1RET | |
| SCHEMBL2730838 | 0.75 | KCNJ1 (0.60) | KCNJ1KCNH2 | |
| SCHEMBL24135371 | 0.74 | KCNJ1 (0.45) | KCNJ1 | |
| SCHEMBL24135400 | 0.71 | KCNJ1 (0.46) | KCNJ1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200109135-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2020-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200109135-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | NR0B1, GRK1, GRIN1 | KCNJ1 562/4885SRC 1665/4885PARP1 2015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.